Notably, overexpression of JMJD5 significantly inhibits NSCLC cell growth and promotes the sensitivity of cells to EGFR TKI, and enhanced exosomal transferring of JMJD5 may provide a novel therapeutic strategy for NSCLC to target EGFR. Here, EGFR is linked to non-small cell lung carcinoma.